化学抗原受体T细胞疗法:在自身免疫性类风湿性疾病中出现的新景观
Xia Lyu1,2,3, Latika Gupta3,4, Eleni Tholouli5
1Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Rheumatology (Oxford, England)
|November 20, 2023
概括
化学抗原受体T细胞 (CAR-T) 疗法对自身免疫性类风湿性疾病显示出有前途. 向CD19的CAR-T可提供快速,无药物缓解,但需要在大型研究中进一步验证.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法已经改变了血液恶性瘤治疗.
- 最近的进展表明,CAR-T针对CD19的疗效在耐火性自身免疫性类风湿性疾病,如狼.
- 与较新的CAR-T方法相比,现有的B细胞枯竭疗法存在局限性.
研究的目的:
- 评估针对CD19的CAR-T在自身免疫性风湿性疾病中的治疗潜力.
- 将CAR-T疗法的疗效和安全性与当前的B细胞枯竭治疗方法进行比较.
- 强调需要进一步临床验证CAR-T疗法在风湿病学.
主要方法:
- 针对CD19的CAR结构在耐火性自身免疫性类风湿性疾病患者中的应用.
- 评估治疗效果,包括反应速度和缓解率.
- 监测与CAR-T疗法相关的不良事件.
主要成果:
- 向CD19的CAR-T在自身免疫性风湿性疾病中表现出快速而深刻的治疗效果.
- 在接受治疗的患者中实现无药缓解.
- 报告了可管理的不良事件,表明了有利的安全概况.
结论:
- 向CD19的CAR-T疗法为耐火性自身免疫性类风湿性疾病提供了高度有效的治疗选择.
- 进一步的大规模,长期的随机受控研究对于确认安全性,疗效和耐用性至关重要.
- 优化CAR-T工程和患者选择将对更广泛的临床实施至关重要.
相关概念视频
Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K


